Amova Asset Management Americas Inc. Has $1.42 Million Holdings in Amgen Inc. $AMGN

Amova Asset Management Americas Inc. trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 23.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,042 shares of the medical research company’s stock after selling 1,583 shares during the period. Amova Asset Management Americas Inc.’s holdings in Amgen were worth $1,422,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the second quarter valued at about $27,000. Evelyn Partners Investment Management LLP acquired a new stake in Amgen in the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute bought a new stake in Amgen in the 2nd quarter valued at approximately $32,000. Cloud Capital Management LLC acquired a new position in Amgen during the 3rd quarter worth approximately $34,000. Finally, Nvwm LLC boosted its position in Amgen by 893.3% during the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock worth $42,000 after acquiring an additional 134 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $367.60 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company has a market capitalization of $198.16 billion, a P/E ratio of 25.83, a P/E/G ratio of 3.76 and a beta of 0.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The stock has a 50 day moving average of $352.53 and a 200-day moving average of $321.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s payout ratio is 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board approved a $2.52 quarterly dividend, payable June 5, 2026, supporting income investors and signaling cash-flow confidence. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen launched a new Phase 3 subcutaneous trial to expand its blinatumomab franchise — a constructive pipeline development that could add long-term value if successful. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11; management comments (CFO and SVP of rare disease) could offer incremental guidance or pipeline color. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Coverage pieces examine post-earnings momentum and valuation (why AMGN has risen ~24% over the past year); useful for context but not single-driver news. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Neutral Sentiment: Reported short-interest data in early March appears erroneous (0 shares / NaN change); treat as noise until reliable data is posted. (No link available)
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals tying OX40 modulation to potential malignancies — this removes a late‑stage asset and raises near-term pipeline risk and uncertainty around R&D priorities. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: An analyst downgrade recommended waiting for a better entry point (rating cut / hold), which can amplify selling pressure after the pipeline news. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Rothschild & Co Redburn boosted their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research note on Tuesday, January 20th. Finally, HSBC restated a “buy” rating and issued a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $354.17.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.